Tidal Investments LLC lessened its holdings in Envista Holdings Co. (NYSE:NVST – Free Report) by 43.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,349 shares of the company’s stock after selling 15,706 shares during the period. Tidal Investments LLC’s holdings in Envista were worth $402,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. Raymond James Trust N.A. lifted its stake in shares of Envista by 3.8% during the 2nd quarter. Raymond James Trust N.A. now owns 28,959 shares of the company’s stock worth $482,000 after buying an additional 1,072 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Envista by 7.7% during the second quarter. Bank of New York Mellon Corp now owns 1,772,262 shares of the company’s stock worth $29,473,000 after acquiring an additional 127,421 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Envista by 13.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,737 shares of the company’s stock worth $594,000 after acquiring an additional 4,121 shares during the period. Innealta Capital LLC acquired a new position in shares of Envista in the second quarter valued at approximately $78,000. Finally, Signaturefd LLC increased its stake in shares of Envista by 85.9% during the second quarter. Signaturefd LLC now owns 5,345 shares of the company’s stock worth $89,000 after purchasing an additional 2,470 shares during the period.
Envista Price Performance
Shares of NYSE:NVST opened at $18.80 on Tuesday. Envista Holdings Co. has a one year low of $15.15 and a one year high of $25.64. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The company has a market cap of $3.24 billion, a price-to-earnings ratio of -2.42, a PEG ratio of 2.71 and a beta of 1.31. The firm has a 50 day simple moving average of $20.14 and a 200 day simple moving average of $18.43.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the company. Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and boosted their price target for the company from $16.00 to $23.00 in a research note on Thursday, October 31st. Robert W. Baird raised their price target on shares of Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Piper Sandler lifted their price objective on shares of Envista from $16.00 to $17.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Wells Fargo & Company initiated coverage on shares of Envista in a research report on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 target price on the stock. Finally, Stifel Nicolaus lifted their price target on shares of Envista from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Envista presently has a consensus rating of “Hold” and an average price target of $20.65.
Check Out Our Latest Stock Report on Envista
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading
- Five stocks we like better than Envista
- Quiet Period Expirations Explained
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- How to Calculate Stock Profit
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- How to Most Effectively Use the MarketBeat Earnings Screener
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.